PATENT CLAIM ANALYSIS

Application Number: 15865695
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "259300"]

Abstract:
The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Claim (Index 15):
A method of treating, ameliorating or preventing one or more conditions comprising the symptom of cognitive deficiency; organic, including symptomatic, mental disorders, dementia; mental retardation; mood affective disorders; neurotic, stress-related and somatoform disorders including anxiety disorders; behavioural and emotional disorders with onset usually occurring in childhood and adolescence, attention deficit hyperactivity syndrome (ADHD) and Autism spectrum disorders; disorders of psychological development, developmental disorders of scholastic skills; schizophrenia and other psychotic disorders; disorders of adult personality and behaviour; mental and behavioural disorders due to psychoactive substance use; extrapyramidal and movement disorders; episodic and paroxysmal disorders, epilepsy; systemic atrophies primarily affecting the central nervous system, ataxia; behavioural syndromes associated with physiological disturbances and physical factors; sexual dysfunction comprising excessive sexual drive; factitious disorders; cognitive impairment being related to perception, concentration, cognition, learning or memory; cognitive impairment being related to age-associated learning and memory impairments; age-associated memory losses; vascular dementia; craniocerebral trauma; stroke; dementia occurring after strokes (post stroke dementia); post-traumatic dementia; general concentration impairments; concentration impairments in children with learning and memory problems; Alzheimer's disease; lewy body dementia; dementia with degeneration of the frontal lobes including Pick's syndrome; parkinson's disease; progressive nuclear palsy; dementia with corticobasal degeneration; amyotropic lateral sclerosis (ALS); Huntington's disease; Multiple Sclerosis; thalamic degeneration; Creutzfeld-Jacob dementia; HIV dementia; schizophrenia with dementia or Korsakoff's psychosis; sleep disorders; bipolar disorder; metabolic syndrome; obesity; diabetis mellitus; hyperglycemia; dyslipidemia; impaired glucose tolerance; disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen; pain disorders; neuropsychiatric symptoms (e.g. depressive symptoms in Alzheimer's disease); mixed dementia; cognitive impairment in schizoaffective disorder; cognitive impairment in bipolar disorder or cognitive impairment in major depressive disorder; in a subject comprising administering to the subject an effective amount of a compound of formula (I) wherein A is selected from the group A a  consisting of wherein above mentioned groups are substituted with one R 5  and one R 6 ; R 1  is selected from the group R 1a  consisting of\n halogen, C 1-3 -alkyl- and C 3-6 -cycloalkyl-\n wherein the above mentioned C 1-3 -alkyl-, and C 3-6 -cycloalkyl- groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, NC\u2014 and HO\u2014; \n \n R 2  is selected from the group R 2a  consisting of\n aryl and heteroaryl,\n wherein the above mentioned aryl and heteroaryl-groups may optionally be substituted with 1 to 5 substituents R 4 ; \n \n R 3  is selected from the group R 3a  consisting of\n H\u2014 and C 1-3 -alkyl-,\n wherein the above mentioned C 1-3 -alkyl-groups may optionally be substituted with 1 to 7 substituents independently from each other selected from the group consisting of halogen; \n \n R 4  is independently from each other selected from the group R 4a  consisting of\n halogen, NC\u2014, HO\u2014, C 1-4 -alkyl- and C 1-3 -alkyl-O\u2014\n wherein the above mentioned C 1-4 -alkyl- and C 1-3 -alkyl-O-groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO\u2014 and F\u2014; \n \n R 5  is selected from the group R 5a  consisting of\n H\u2014, halogen, NC\u2014, HO\u2014 and C 1-3 -alkyl-,\n wherein the above mentioned C 1-3 -alkyl-group may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO\u2014 and F\u2014 \n or R 5  and R 6  together form an group O\u2550; \n \n R 6  is selected from the group R 6a  consisting of\n H\u2014, halogen, NC\u2014, HO\u2014 and C 1-3 -alkyl-,\n wherein the above mentioned C 1-3 -alkyl-group may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO\u2014 and F\u2014 \n or R 5  and R 6  together form a group O\u2550; \n \n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 86.0
- Lexical Diversity: 1.31915
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13951531', '14511238', '14433769', '14166012', '12084814']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.775359831352465
- 35 USC 102 Novelty (BERT): 0.5304541465670128
- Combined Prediction Score: 0.7508692628739199
- Mean Citation Score: 311.9217660000001
- Max Citation Score: 350.06256
- Similarity Product: 225.4991476351548

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test